Cerevel Therapeutics Securities Fraud Lawsuit
Analysis based on 17 articles · First reported Apr 18, 2025 · Last updated Apr 29, 2025
The class action lawsuit against Coeptis Therapeutics Holdings for alleged securities fraud could lead to significant financial penalties for Coeptis Therapeutics Holdings and Bain Capital, potentially impacting their stock prices and reputations. Investors who sold Coeptis Therapeutics Holdings stock during the specified period or held shares for the merger vote may recover losses, affecting market confidence in secondary offerings and M&A transparency.
Levi & Korsinsky, LLP has notified investors of a class action securities lawsuit against Coeptis Therapeutics Holdings. The lawsuit alleges that Coeptis Therapeutics Holdings and its controlling shareholder, Bain Capital, engaged in securities fraud by omitting material facts regarding AbbVie Inc.'s interest in acquiring Coeptis Therapeutics Holdings at a price significantly higher than its October 16, 2023 secondary stock offering price of $22.81 per share. This alleged omission artificially deflated Coeptis Therapeutics Holdings's stock price, allowing Bain Capital to acquire shares at a depressed price while possessing nonpublic information, resulting in a $120 million windfall after AbbVie Inc. announced its agreement to acquire Coeptis Therapeutics Holdings for $45 per share on December 6, 2023. Additionally, Coeptis Therapeutics Holdings's January 18, 2024 Proxy statement is accused of misleading investors about the nature and timing of AbbVie Inc.'s interest. Investors who suffered losses during the period from October 11, 2023, through August 1, 2024, or held shares as of January 8, 2024, are urged to join the lawsuit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard